Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IBRX NASDAQ:NUVL NASDAQ:PRAX NASDAQ:ZLAB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIBRXImmunityBio$7.10-1.4%$7.55$1.95▼$12.43$7.54B0.0313.86 million shs8.79 million shsNUVLNuvalent$123.25-0.2%$104.21$71.13▼$123.62$9.75B1.153.98 million shs7.24 million shsPRAXPraxis Precision Medicines$266.58+7.5%$319.32$37.19▼$366.52$6.91B2.71467,933 shs423,170 shsZLABZai Lab$17.07-3.2%$20.00$15.96▼$42.00$2.00B0.78912,454 shs1.31 million shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIBRXImmunityBio-1.39%+2.60%-12.88%-15.38%+119.14%NUVLNuvalent-0.16%+35.51%+17.14%+25.86%+60.25%PRAXPraxis Precision Medicines+7.50%+4.95%-23.00%-9.31%+497.71%ZLABZai Lab-3.23%+2.71%-16.61%-7.08%-58.77%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIBRXImmunityBio$7.10-1.4%$7.55$1.95▼$12.43$7.54B0.0313.86 million shs8.79 million shsNUVLNuvalent$123.25-0.2%$104.21$71.13▼$123.62$9.75B1.153.98 million shs7.24 million shsPRAXPraxis Precision Medicines$266.58+7.5%$319.32$37.19▼$366.52$6.91B2.71467,933 shs423,170 shsZLABZai Lab$17.07-3.2%$20.00$15.96▼$42.00$2.00B0.78912,454 shs1.31 million shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIBRXImmunityBio-1.39%+2.60%-12.88%-15.38%+119.14%NUVLNuvalent-0.16%+35.51%+17.14%+25.86%+60.25%PRAXPraxis Precision Medicines+7.50%+4.95%-23.00%-9.31%+497.71%ZLABZai Lab-3.23%+2.71%-16.61%-7.08%-58.77%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIBRXImmunityBio 2.71Moderate Buy$14.20100.00% UpsideNUVLNuvalent 2.20Hold$131.156.41% UpsidePRAXPraxis Precision Medicines 2.95Moderate Buy$572.72114.84% UpsideZLABZai Lab 2.63Moderate Buy$45.83168.50% UpsideCurrent Analyst Ratings BreakdownLatest ZLAB, IBRX, NUVL, and PRAX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/10/2026NUVLNuvalent Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform6/10/2026NUVLNuvalent GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$151.00 ➝ $124.006/10/2026NUVLNuvalent UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$138.00 ➝ $124.006/10/2026NUVLNuvalent UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$138.00 ➝ $124.006/9/2026NUVLNuvalent Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$124.006/9/2026NUVLNuvalent TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$124.006/9/2026NUVLNuvalent BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$152.00 ➝ $124.006/9/2026NUVLNuvalent Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$122.856/9/2026NUVLNuvalent Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$124.006/9/2026NUVLNuvalent Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Market Perform6/4/2026ZLABZai Lab Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)(Data available from 6/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIBRXImmunityBio$113.29M65.64N/AN/A($0.51) per share-13.92NUVLNuvalentN/AN/AN/AN/A$15.95 per shareN/APRAXPraxis Precision Medicines$8.55M869.27N/AN/A$34.85 per share7.65ZLABZai Lab$460.16M4.21N/AN/A$6.39 per share2.67Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIBRXImmunityBio-$351.40M-$0.85N/AN/AN/A-606.15%N/A-59.53%8/4/2026 (Estimated)NUVLNuvalent-$425.38M-$6.06N/AN/AN/AN/A-40.11%-35.43%8/6/2026 (Estimated)PRAXPraxis Precision Medicines-$303.27M-$13.37N/AN/AN/AN/A-43.02%-40.22%8/3/2026 (Estimated)ZLABZai Lab-$175.54M-$1.62N/AN/AN/A-39.29%-24.32%-15.52%8/6/2026 (Estimated)Latest ZLAB, IBRX, NUVL, and PRAX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026IBRXImmunityBio-$0.08-$0.62-$0.54-$0.62$43.07 million$44.21 million5/7/2026Q1 2026NUVLNuvalent-$1.35-$1.39-$0.04-$1.39$0.49 millionN/A5/7/2026Q1 2026PRAXPraxis Precision Medicines-$3.58-$3.20+$0.38-$3.20$0.10 millionN/A5/7/2026Q1 2026ZLABZai Lab-$0.5262-$0.46+$0.0662-$0.50$108.43 million$99.61 million4/1/2026Q1 2026ZLABZai LabN/A-$0.50N/A-$0.50N/A$99.61 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthIBRXImmunityBioN/AN/AN/AN/AN/ANUVLNuvalentN/AN/AN/AN/AN/APRAXPraxis Precision MedicinesN/AN/AN/AN/AN/AZLABZai LabN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIBRXImmunityBioN/A6.676.66NUVLNuvalentN/A16.1416.14PRAXPraxis Precision MedicinesN/A15.8815.88ZLABZai LabN/A2.402.19Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIBRXImmunityBio8.58%NUVLNuvalent97.26%PRAXPraxis Precision Medicines67.84%ZLABZai Lab41.65%Insider OwnershipCompanyInsider OwnershipIBRXImmunityBio69.48%NUVLNuvalent5.02%PRAXPraxis Precision Medicines2.70%ZLABZai Lab4.88%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIBRXImmunityBio5901.05 billion319.65 millionOptionableNUVLNuvalent4079.00 million75.03 millionOptionablePRAXPraxis Precision Medicines11027.88 million27.13 millionOptionableZLABZai Lab1,784113.41 million107.88 millionOptionableZLAB, IBRX, NUVL, and PRAX HeadlinesRecent News About These CompaniesPfizer, Zai Lab win China nod for cervical cancer therapy TivdakJune 9, 2026 | msn.comZai Lab Receives China NMPA Approval of TIVDAK® (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical CancerJune 8, 2026 | businesswire.comZai Lab (ZLAB) Is Down 6.0% After Leadership Shake-Up And 2026 Data Focus Has The Bull Case Changed?June 6, 2026 | finance.yahoo.comZai Lab (ZLAB) Announces Senior Leadership ChangesJune 6, 2026 | finance.yahoo.com5 Stocks That Have the Potential to Rise 1000%June 5, 2026 | insidermonkey.comZai Lab (ZLAB) Q1 2026 Earnings TranscriptJune 2, 2026 | fool.comZai Lab announces departure of president and COO Josh SmileyMay 22, 2026 | msn.comZai Lab announces departure of president and COO Josh SmileyMay 22, 2026 | msn.comZai Lab Announces Changes to Senior Leadership TeamMay 21, 2026 | businesswire.comZai Lab (NASDAQ:ZLAB) CEO Ying Du Sells 50,000 SharesMay 16, 2026 | insidertrades.comZai Lab: A Speculative Bet On Global Oncology, With A Greater China Bag AttachedMay 14, 2026 | seekingalpha.comZai Lab Limited 2026 Q1 - Results - Earnings Call PresentationMay 11, 2026 | seekingalpha.comZai Lab Limited (NASDAQ:ZLAB) Analysts Are Cutting Their Estimates: Here's What You Need To KnowMay 11, 2026 | finance.yahoo.comZai Lab wins FDA fast track status for cancer drug Zocilurtatug PelitecanMay 11, 2026 | msn.comZai Lab Receives U.S. FDA Fast Track Designation for Zocilurtatug Pelitecan (Zoci), a DLL3-Targeting ADC, for Treatment of Extrapulmonary Neuroendocrine Carcinomas (epNECs)May 11, 2026 | businesswire.comZai Lab Limited (ZLAB) Q1 2026 Earnings Call TranscriptMay 7, 2026 | seekingalpha.comZai Lab Limited (ZLAB) Reports Q1 Earnings: What Key Metrics Have to SayMay 7, 2026 | zacks.comZai Lab Announces First Quarter 2026 Financial Results and Recent Corporate UpdatesMay 7, 2026 | finance.yahoo.comAssessing Zai Lab (ZLAB) Valuation After Recent Share Price Momentum And Analyst Target ResetApril 29, 2026 | finance.yahoo.comZai Lab Limited (ZLAB) Discusses Intracranial Activity of a New Therapy in Small Cell Lung Cancer With Brain Metastases - SlideshowApril 22, 2026 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 20265 Stocks Winning the AI Race While Everyone Watches NVIDIABy Bridget Bennett | May 26, 2026The Smart Glasses Gold Rush Is Leaving Old-School Eyewear BehindBy Jeffrey Neal Johnson | May 24, 20263 Space Infrastructure Stocks Gaining Momentum Ahead of the SpaceX IPOBy Ryan Hasson | May 20, 2026Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 BillionBy Jeffrey Neal Johnson | June 11, 2026ZLAB, IBRX, NUVL, and PRAX Company DescriptionsImmunityBio NASDAQ:IBRX$7.10 -0.10 (-1.39%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$7.10 +0.01 (+0.07%) As of 06/12/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.Nuvalent NASDAQ:NUVL$123.25 -0.20 (-0.16%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$123.25 +0.00 (+0.00%) As of 06/12/2026 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.Praxis Precision Medicines NASDAQ:PRAX$266.58 +18.60 (+7.50%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$270.00 +3.42 (+1.28%) As of 06/12/2026 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.Zai Lab NASDAQ:ZLAB$17.07 -0.57 (-3.23%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$17.08 +0.01 (+0.06%) As of 06/12/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution TJX: Retail’s Apex Predator Feasts on Inflation Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears This Energy Stock Has Quietly Soared 130% in a Year Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
